Prescription Description
| Prescription ID | TCMF7391 |
| Pinyin Name | Xie Bai San |
| Chinese Name | 泻白散 |
| English Name | Xie Bai Powder |
| Function Description | 肺热咳嗽, 甚则气喘, 皮肤蒸热, 日晡尤甚 |
| Indications | None |
| Disease ICD-11 Category | |
| Human Tissues Associated with Indication | Lung |
| Reference | Taiwan Herbal Pharmacopeia 2nd Edition English Version |
| Reference Book/link | https://www.mohw.gov.tw/cp-3690-39025-2.html |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH449 | Cortex lycii radicis | 地骨皮 | TCMH449 | |
| TCMH2629 | Cortex mori radicis praeparata | 桑白皮 | TCMH2629 | |
| TCMH628 | Glycyrrhiza uralensis | 甘草 | TCMH628 | ITSAM892-14 |
| TCMH1146 | Oryza sativa | 粳米 | TCMH1146 | GBVD4258-11, GBVD4257-11 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
| TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
| TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
| TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
| TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT807 | SLC22A12 | Solute carrier family 22 member 12 | Transporter | Q96S37 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
| TCMT926 | LSS | Lanosterol synthase | Isomerase | P48449 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1212 | Verticillium dahliae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1221 | Human herpesvirus 4 |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 13.8974 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.7687 |
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 9.55484 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.94458 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.57546 |
| [BP] GO:0008152 | metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 7.44858 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FUT7, GBA2, TYR, XDH | 6.98936 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, HSD11B2, HSD17B2, TYR | 5.57149 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.47612 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.43621 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, MMP2, MMP9, TYR | 5.39696 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 4.84747 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.84747 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FUT7, GBA2, HSD17B1, HSD17B2, MMP1, MMP2, PTPN1, TNKS, TNKS2, TYR, XDH | 4.79723 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, TYR | 4.63257 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.62449 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.55735 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.14489 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 3.89669 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.89521 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.75925 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, TYR | 3.34998 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, HSD11B2 | 3.23031 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.23031 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, MMP2, TYR | 3.01903 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 2.95867 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, GBA2, TYR | 2.93025 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 2.93025 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.74601 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, HSD11B2, MMP2 | 2.65703 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, MMP2, MMP9, TYR | 2.57265 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.55066 |
| [BP] GO:0032502 | developmental process | ACHE, AKR1B1, ALPL, BCL2, CA2, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FUT7, GBA2, HSD11B1, HSD17B2, MMP2, MMP9, TNKS2, TYR | 2.54803 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.36896 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.33699 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.33699 |
| [BP] GO:0048856 | anatomical structure development | ACHE, AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, GBA2, HSD11B1, HSD17B2, MMP9, TYR | 2.33699 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.27265 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.22175 |
| [BP] GO:0009056 | catabolic process | ACHE, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FUT7, GBA2, MMP1, MMP2, MMP9, XDH | 2.21796 |
| [BP] GO:0022414 | reproductive process | AKR1B1, ALPL, BCL2, CDC25B, CYP19A1, CYP1A1, ESR1, ESRRB, HSD11B2, HSD17B2, MMP2, MMP9 | 2.18074 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TNKS, TNKS2, XDH | 2.11859 |
| [BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.11338 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.10736 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.10736 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.10736 |
| [BP] GO:0010647 | positive regulation of cell communication | AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, MMP9, PTPN1, TNKS, TNKS2, XDH | 2.08223 |
| [BP] GO:0023056 | positive regulation of signaling | AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, MMP9, PTPN1, TNKS, TNKS2, XDH | 2.06831 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.54014 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA4, CA5A, CA5B, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 1.53184 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.19027 |
| [CC] GO:0000242 | None | TNKS, TNKS2 | 0.920187 |
| [CC] GO:0031233 | None | CA4, F3 | 0.920187 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 19.3184 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PTPN1, TNKS, TYR, XDH | 16.4714 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.9581 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.6949 |
| [MF] GO:0003824 | catalytic activity | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 10.3564 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PTPN1, TNKS | 10.2749 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 7.94458 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 6.96624 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 6.35123 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 6.21723 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, HSD17B1, MMP1, MMP2, MMP9, PTPN1, TNKS, TNKS2, TYR, XDH | 6.15245 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.53603 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.63057 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.94738 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.88232 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.77313 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.72766 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.6089 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.21439 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 3.02538 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.94313 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 2.93025 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.81435 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB | 2.80538 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB | 2.80538 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.74601 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.74601 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB | 2.54803 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, XDH | 2.54803 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.18745 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.10736 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 21.048 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 10.8321 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.7277 |
| Metabolic pathways_Homo sapiens_hsa01100 | AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 5.5849 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.5874 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.6124 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | MMP2, MMP9, ESR1, ESR2 | 3.2667 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.4793 |
| Bladder cancer_Homo sapiens_hsa05219 | MMP1, MMP2, MMP9 | 3.1119 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, MMP9, CDC25B | 2.5514 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.556 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, MMP1, MMP2, BCL2, MMP9 | 2.0814 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2, BCL2, F3 | 2.102 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2, MMP9 | 1.8011 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | MMP2, MMP9, ESR1 | 1.4467 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.5385 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.4297 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.9165 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.4467 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.1396 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.9983 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.4246 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.156 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.3335 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.9158 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.2849 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.969 |
| Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.1214 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 1.0492 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 1.0958 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.9566 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.8362 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2 | 0.6234 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.6484 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.6484 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.6151 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.6472 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.6531 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.6484 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.6857 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6472 |
| GnRH signaling pathway_Homo sapiens_hsa04912 | MMP2 | 0.6151 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.6057 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6151 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.6043 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1 | 0.586 |
| TNF signaling pathway_Homo sapiens_hsa04668 | MMP9 | 0.586 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.5991 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.6484 |
| Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.6151 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.5406 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6484 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6073 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6286 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.5763 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.5763 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | MMP1 | 0.6484 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.5406 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6234 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.6073 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5763 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.4872 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.5406 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.5406 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.5406 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.5306 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | BCL2 | 0.5763 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.48 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.3799 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.4492 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.7307 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.48 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.4493 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | MMP9 | 0.48 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4753 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.7151 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.7307 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.7307 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.7307 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.7773 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.3215 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8693 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8523 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8693 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8807 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8768 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 1.0122 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0932 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.3674 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples